SCHEMBL16293432

SCHEMBL16293432

CC(CO)c1cccc(B(O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 7/20 0.48
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MGLL Q99685 2/20 0.41
▸ LPL P06858 2/20 0.41
▸ LIPG Q9Y5X9 2/20 0.41
▸ ABCB11 O95342 1/20 0.41
▸ TRPA1 O75762 3/20 0.39
▸ HDAC4 P56524 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ CA4 P22748 1/20 0.37
▸ CA6 P23280 1/20 0.37
▸ CA5A P35218 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ CA5B Q9Y2D0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16293433 1.00 ENPP2 (0.48) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL3787098 0.85 HDAC4 (0.53) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL20129360 0.82 TRPA1 (0.49) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL5247771 0.82 ABCB11 (0.50) KDM4EALDH1A1ABCB11TRPA1HDAC4
SCHEMBL31430960 0.80 ENPP2 (0.50) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL129343 0.80 ENPP2 (0.50) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL2722929 0.80 FFAR1 (0.46) ENPP2KDM4EALDH1A1MGLLLPL
Hydrochloric Acid SCHEMBL893960 0.79 ENPP2 (0.48) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL1812495 0.79 ENPP2 (0.48) ENPP2KDM4EALDH1A1MGLLLPL
SCHEMBL12284676 0.77 HDAC4 (0.44) ABCB11TRPA1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657006-B2 Macrocyclic factor VIIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-23 — — US disclosed
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-04-28 — — US disclosed
EP-3008052-A1 MACROCYCLIC FACTOR VIIA INHIBITORS Bristol-Myers Squibb Company (US) 2016-04-20 — — EP disclosed
WO-2014201073-A9 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-08 — — WO disclosed
WO-2014201073-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS F7, F12, F5 ENPP2 197/4885KDM4E 1708/4885ALDH1A1 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback